Cambridge Startup T-Therapeutics Raises €27.5M To Boost Immune Therapy

New investors Tencent and BGF joined the Series A syndicate, alongside existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, and the University of Cambridge Venture Fund.

Following the initial €50.7 million ($59 million), the Series A total now stands at €78.2 million ($91 million).

Theodora Harold, CEO of T-Therapeutics, said: “Our transformative medicines tackle upstream disease-drivers that can have pan-indication impact. We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support.”

This Series A extension places UK-based T-Therapeutics prominently within the 2025 European immuno-oncology funding landscape.

Read Also - Lative Raises €6.4M To Expand AI-Powered Sales Planning Platform

In France, Adcytherix raised €105 million to advance its antibody-drug conjugate pipeline while Spain’s Adaptam Therapeutics secured €3 million for therapies targeting immunosuppressive myeloid cells.

While these companies focus on adjacent modalities, they collectively highlight strong and sustained investor interest in European immunotherapy and oncology innovation. With roughly €108 million invested across the sector, T-Therapeutics’ €78.2 million Series A represents a significant share of visible activity this year.

Graziano Seghezzi, Managing Partner at Sofinnova Partners, said: “The existing investors co-founded T-Therapeutics to push the boundaries of bispecific technology. This additional capital enables us to expand into T cell subset depletion, one of the most exciting areas in immunology, while continuing to advance oncology programmes.

“We are now ideally positioned to address both cancer and autoimmune disease, two broad disease areas with critical unmet medical needs, with a platform that unlocks targets previously considered undruggable.”

Founded in 2022 and spun out from the University of Cambridge, T-Therapeutics is developing next-generation TCR (TTCR) therapeutics to harness T cell biology for safe and effective treatments of cancer and autoimmune diseases.

The team brings together expertise in mouse genome engineering, single-cell genomics, biopharmaceutical development, machine learning, and structural biology, supported by a collaborative, innovative culture.

Its OpTiMus TCR platform reportedly generates a nearly unlimited repertoire of fully human, high-specificity TCRs, enabling access to previously undruggable intracellular targets. Combined with proprietary next-generation CD3 T cell engagers (TCEs) engineered for potency, safety, and optimal pharmacokinetics, these TCRs form first-in-class bispecific drug candidates.

T-Therapeutics’ pipeline focuses on upstream disease drivers with pan-indication potential to deliver meaningful clinical benefits to patients.

Luke Rajah, Partner at BGF, added: “This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines. Backed by a syndicate of world-class life sciences investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics. We are proud to support the team and help catalyse their programmes towards the clinic.”

T-Therapeutics will use the additional proceeds to drive its pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic, including the further exploration of new therapeutic strategies such as T cell subset depletion.

Their lead asset in oncology exploits a pan-tumour driver target, applicable across multiple different solid tumour types. Its lead immunology programme is a pan-autoimmune bispecific designed for precision immune reset, achieved by the selective depletion of pathogenic immune cells.

About T-Therapeutics

T-Therapeutics, spun out from the University of Cambridge, is a next-generation TCR company rooted in world-leading science. Using its proprietary OpTiMus® platform and fully humanized TCR mice, the company generates a virtually unlimited repertoire of unique, antigen-specific human TCRs to develop optimized therapeutics for cancer and autoimmune diseases.